SNDX (Syndax Pharmaceuticals) Minority Interest: $0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SNDX Syndax Pharmaceuticals Inc SNDX
27 GF Score
Price $20.37
! 5 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Minority Interest?

Syndax Pharmaceuticals SNDX -0.15% 27 Minority Interest is $0.00 Mil as of Jun. 2026. GuruFocus rates SNDX with a GF Score™ of 27/100. The stock has 5 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Syndax Pharmaceuticals's minority interest for the quarter that ended in Jun. 2026 was $0.00 Mil.

Syndax Pharmaceuticals Minority Interest Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Minority Interest Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syndax Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
SNDX
27GF Score
Syndax Pharmaceuticals Inc SNDX
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of $0.00 Mil mean?
Syndax Pharmaceuticals (SNDX) has a Minority Interest of $0.00 Mil as of Jun. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Syndax Pharmaceuticals.
Is Syndax Pharmaceuticals' Minority Interest too high?
Syndax Pharmaceuticals' current Minority Interest is $0.00 Mil. Overall, Syndax Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Minority Interest compare to FTRE and KARD?
Syndax Pharmaceuticals' Minority Interest of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Syndax Pharmaceuticals. Syndax Pharmaceuticals's current Minority Interest is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (SNDX) has a current Minority Interest of $0.00 Mil. The current Minority Interest is $0.00 Mil. Syndax Pharmaceuticals' overall GF Score™ is 27/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Syndax Pharmaceuticals (SNDX), the current Minority Interest is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges 1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
27GF Score

Get the complete analysis for SNDX

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.37
Price